Subcutaneous administration of Lyso‐phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse model
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Pharmaceutics"
DOI: 10.1016/j.ijpharm.2018.07.018
Abstract: ABSTRACT A major complication with enzyme replacement therapy of Factor VIII (FVIII) in Hemophilia A (HA) is the development of anti‐drug antibodies. Recently, we have shown that FVIII administration in the presence of heterogeneous phosphatidylserine… read more here.
Keywords: administration; tolerance towards; administration lyso; tolerance ... See more keywords